StreetAlpha.app
Home › Stocks › DMRA

Damora Therapeutics, Inc. (DMRA)

Healthcare
$23.22
▼ −4.44%
LAST CLOSE · NOV 20

Damora Therapeutics is a Waltham biopharmaceutical company developing antibody treatments for blood disorders. It last closed at $23.22 on Nov 20, down 4.44% on the day. For the quarter ended Sep 2026, DMRA reported EPS of -$0.40. Over its last 3 reports the stock moved an average of 12.1% the session after earnings. Over the last 12 months DMRA insiders bought $253K of stock on the open market and sold $31K, according to SEC Form 4 filings.

AI Auto Pilots
Is DMRA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold DMRA.

Key Stats

Last 12 months
Results
Net income
−$291.7M
Valuation
Market cap
$1.4B
61.9M shares
P/E
–
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$349.7M
At Sep 30
Shareholder equity
$495.8M
Shares outstanding
61.9M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$51.8M−$51.8MFY2021FY2022: −$61.6M−$61.6MFY2022FY2023: −$38.3M−$38.3MFY2023FY2024: −$21.4M−$21.4MFY2024FY2025: −$209.8M−$209.8MFY2025

From DMRA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Last report
Mar 10
2026 · next date not set yet
Reported EPS
-$0.40
Quarter ended Sep 2026
Year ago EPS
-$2.36
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$5.23Dec '24Mar 2025: -$1.92Mar '25Jun 2025: -$2.60Jun '25Sep 2025: -$2.36Sep '25Dec 2025: $10.86Dec '25Mar 2026: -$0.62Mar '26Jun 2026: -$0.39Jun '26Sep 2026: -$0.40Sep '26Latest -$0.40
Revenue by quarter
Not enough quarters on file yet.
How DMRA moved after its last 3 reports
Average move the session after a report ±12.1%
Mar 10, 2026Time not announced−11.1%
Jan 6, 2023Time not announced+24.6%
Jan 5, 2021After the close+0.5%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on DMRAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on DMRA
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on DMRA

Technical Analysis

DMRA · as of the Nov 20 close · updated each morning
Bounce inside a longer downtrend

The stock is 3% above its 20 day and 7% above its 50 day average. It is 10% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 54). The nearest support is the Pivot S1 at $22.73, and the nearest resistance the Pivot at $23.62.

Short trendBullish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityNormal, 7.2%/day
Key levels
$38.3352 week high+65.1%
$25.75100 day average+10.9%
$25.44200 day average+9.6%
$25.07Swing high (Nov 11)+8.0%
$24.11Pivot R1+3.8%
$23.62Pivot+1.7%
$23.22Last close
$22.73Pivot S1−2.1%
$22.5620 day average−2.8%
$21.7050 day average−6.5%
$21.10Swing low (Nov 13)−9.1%
$15.7652 week low−32.1%
Indicators
RSI (14)54.06Middle of its rangeNeutral
MACD0.40Above its signal lineBullish
Stochastic63.7Middle of its rangeNeutral
ADX (14)21.1Weak trend
Williams %R-42.8Oversold below −80, overbought above −20Neutral
CCI (20)90.7Oversold below −100, overbought above 100Neutral
Rate of change−2.0%Change over 10 sessionsBearish
ATR (14)$1.67Typical daily range, 7.2% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Below
MA 200Below
What happened before, for DMRA

What happened before

See how DMRA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow DMRA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How DMRA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for DMRAHow many large options trades hit DMRA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

DMRA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲107 buying vs 2 selling
  • ▲Held by funds +95.8 pts
  • ▲Funds holding +108
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding1113+3600.0%
In funds' top 1040–
Held by funds95.9%0.1%+95.8 pts
New / increased107 / 03 / 0+3466.7%
Reduced / sold out2 / 00 / 0–
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See DMRA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

DMRA Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$253K1 buy · 1 insider
Sold$31K4 sales · 3 insiders
2026-01 sold $23K2026-07 sold $7K2026-09 bought $253KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 25Jennifer JarrettDirector, President and CEOBuy12,500$20.23$253K
Jul 6Garrett WinslowGeneral CounselSale245$29.98$7K
Jan 2Lori FirmaniCFOSale135$21.41$3K
Jan 2Garrett WinslowGeneral CounselSale255$21.38$5K
Jan 2Hans T. SchambyeCEOSale700$21.38$15K
Jul 3, 2025Lori FirmaniInterim CFOSale147$3.39$498
Every insider buy and sale for DMRA over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See DMRA insider trades →

From SEC Form 4 filings by DMRA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DMRA is in one of them and how their past DMRA trades turned out.

DMRA in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered DMRA in an article yet. Here's the latest on the wider market.

About Damora Therapeutics

Damora Therapeutics is a biopharmaceutical company based in Waltham, Massachusetts, that develops treatments for blood disorders. Its lead candidate, DMR-001, is an antibody designed to target mutant calreticulin, a protein that drives essential thrombocythemia and myelofibrosis, two myeloproliferative neoplasms that affect the bone marrow. The company is also developing two related candidates for the same group of disorders. Its intended patients are people living with these conditions, and none of its candidates are on the market yet.

Headquarters
Waltham, MA